Afgeronde projecten

In dit overzicht vindt u informatie over afgeronde onderzoeken waarbij data van SHM zijn gebruikt. De lijst is gefilterd en toont alleen projecten die beschikbaar zijn voor een breed publiek. De informatie die nu volgt is Engelstalig.

SHM no.

Project title and publication details

Authors
I15142

Use of regular outpatient medication in HIV/HCV co-infected patients in the Netherlands

Smolders E., Buger D, Arends J, van der Valk M, Brinkman K, Rijnders B, Dofferhof T.
I15022

Community viral load as a tool for HIV surveillance in the Netherlands and South Africa

E. Op de Coul, R. Bolijn, J. Heijne, A. van Sighem, 
M. Kretzschmar, HIV Behandelaar
I14157

Overlap between HIV and HCV networks among MSM with HIV/HCV coinfection

J. Vanhommerig, J. Schinkel, D. Bezemer, T. van de laar, A. van Sighem, C. Smit, M. Prins
I14144

Geographical Information System to determine high prevalence aeras of targeted screening and early case-finding

I. Joore, J. van Bergen, E. op de Coul, A. van Sighem, J. Prins, S. Geerlings
I14096

Primary and recurrent venous thromboembolism in Hiv-1 (PREDICT study)

J. Borjas-Howard, B.J.A. Rijnders, C. Rokx, Y.I.G.V. Tichelaar, A. Verbon, K. Meijer
I14201

Failure of donor selection: what can the virus of the donor tell us?

Paper: Phylogenetic evidence for underreporting of male-to-male sex among human immunodeficiency virus-infected donors in the Netherlands and Flanders
van de Laar TJ, Bezemer D, van Laethem K, vandewalle G, de Smet A, van Wijngaerden E, Claas EC, van Sighem AI, Vandamme AM, Compernolle V, Zaaijer HL.
Transfusion. 2017 May;57(5):1235-1247. doi: 10.1111/trf.14097. Epub 2017 Apr 4.

 T. van de Laar, D. Bezemer, H. Zaaijer, P. van Switten, A. van Sighem, E. Vlaas, V. Compernolle, G. Vanderwalle, A. de Smet, K. van Laethem, A. Vandamme
I13061

Factors associated with time to HIV RNA suppression in women with HIV infection starting antiretroviral treatment during pregnancy

Paper: Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women
van Snippenburg W, Nellen FJB, Smit C, Wensing AMJ, Godrfried MH, Mudrikova T for te ATHENA cohort
J Virus Erad. 2017 Jan; 3(1): 34–39.

 T. Mudrikova, W. van Snippenburg, A. Wensing, J. Nellen, M. Godfried, C. Smit
I13059

Clinical, Immunological, Virological and Social outcomes of cART treated HIV infected children after transition into adult health care services (CLIVIA study)

Paper: Virological and social outcomes of HIV-infected adolescents and young adults in the Netherlands before and after transition to adult care
Weijsenfeld AM, Smit C, Cohen S, Wit FWNM, Mutschelknauss M, van der Knaap LC, van Zonneveld LM, Zomer BJ, Nauta N, Patist JC, Kuipers-Jansen MHJ, Smit EP, Blokhuis C, Pajkrt D.
Clin Infect Dis. 2016 Oct 15;63(8):1105-1112. doi: 10.1093/cid/ciw487. Epub 2016 Jul 20.

A.M. Weijsenfeld, M. Mutschelknauss, F.J.B. Nellen, C. Smit, D. Pajkrt, L. van der Knaap, H. de Jonge, N. Nauta, R.Strik-Albers
I14082

HIV testing and couselling in eneral practices in the Netherlands

Paper: Missed opportunities to offer HIV tests to high-risk groups during general practitioners STI-related consultations: an observational study
Joore IK, Reukers DFM, Donker GA, van Sighem AI, Op de Coul ELM, Prins JM, Geerlings SE, Barth RE, van Bergen JEAM, van den Broek IV. 
http://bmjopen.bmj.com/content/6/1/e009194

E. Op de Coul, I. van den Boek, I. Joore, D. Reukers, J. van Bergen, A. van Sighem
I13153

Factors associated with late diagnosis of HIV in the Netherlands

E. Op de Coul, A. van Sighem, K. Brinkman, M. van der Ende, S. Geerligns, P. Reiss
I13087

Dutch protease for hepatitis C in HIV-infected patients - study (DECIDE-study)

Paper: Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients
Arends JE, van der Meer JT, Posthouwer D, Kortmann W, Brinkman K, van Assen S, Smit C, van der valk M, van der Ende M, Schinkel J, Reiss P, Richter C. Hoepelman AI. 
Neth J Med. 2015 Aug;73(7):324-30.

J.E. Arends, A.I.M. Hoepelman, K.Brinkman, J. van der Meer, I. van de Ende, C. Richter, E.F. Schippers, D. de Vries-Sluijs, J. Schinkel, C. Smit
I13018

I13018 Efficacy of lamivudine compared to emtricitabine in nevirapine and efavirenz based antiretroviral therapy: an observational retrospective cohort study Date of approval: 3 June 2013

Paper: Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort
Rokx C, Fibriani A, van de Vijver DA, Verbon A, Schutten M, Gras L, Rijnders BJAIDS Therapy Evaluation in the Netherlands National Observational Cohort
Clin Infect Dis. 2015 Jan 1;60(1):143-53. Abstract

Rokx C, Rijnders B, Verbon A, van de Vijver D
I12106

Differences between HIV-1-infected children in the Netherlands from different countries of origin
Date of approval: April 2013
Paper:Country of birth does not influence long-term clinical, virologic, and immunological outcome of HIV-infected children living in the Netherlands: a cohort study comparing children born in the Netherlands with children born in sub-Saharan Africa.
Cohen S, van Bilsen WP, Smit C, Fraaij PL, Warris A, Kuijpers TW, Geelen SP, Wolfs TF, Scherpbier HJ, van Rossum AM, Pajkrt D
J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):178-185 Abstract

Pajkrt D, van Bilsen W, Cohen S

I12001

Low mother-to-child transmission rate of hepatitis C in cART-treated HIV-1 infected mothers
Date of approval: 9 February 2012
Paper: Low mother-to-child-transmission rate of hepatitis C virus in cART treated HIV-1 infected mothers
Snijdewind IJM, Smit C, Schutten M, Nellen FJB, Kroon FP, Reiss P,  van der Ende ME
J Clin Virol. 2015 Jul;68:11-5 Abstract

Van de Ende M, Snijdewind I, Smit C, Schutten M, Hartwig N, de Wolf F

I11072 Virologic response after initiation of triple-class antiretroviral therapy in patients with primary and chronic HIV Infection
Date of approval: 6 July 2011
Paper: Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection.
Grijsen ML, Holman R, Wit FW, Gras L, Lowe SH, Brinkman K, de Wolf F, Prins JM.
AIDS. 2012 Sep 24;26(15):1974-7. Abstract
M. Grijsen
I11010 The effect of Maraviroc on serum markers
Date of approval: 9 February 2011
Poster: Maraviroc Intensification in Patients with Suboptimal Immunological Recovery Despite Virological Suppressive HAART: a 48-week, Placebo-controlled Trial
van Lelyveld S.
Poster at NCHIV 2013 (no. 55)
V. van der Pas
I10270 Predictors for Pneumocystis jirovecii pneumonia (PJP) during HAART era in ATHENA cohort
Date of approval: 24 March 2011
Paper: Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands; host or environmental factors?
Schoffelen AF, van Lelyveld SF, Barth RE, Gras L, de Wolf F, Netea MG, Hoepelman AI.
AIDS. 2012 Dec 31. [Epub ahead of print] Abstract
S. van Lelyveld
A. Hoepelman
L. Gras
S. Hermans
I10053 Schatting van de onderrapportage van HIV geinfecteerde TBC patienten in Nederland
Date of approval: 13 January 2011
F. van Leth, F. Wit e.a.
I05511 Influence of HIV-1 co-receptor usage on the clinical course of infection under HAART and the outcome of antiretroviral therapy
Date of approval: October 2005
H. Schuitemaker, 
K. Brinkman
I09050 Contribution of multiple genetic variants, previously validated in genome-wide analyses, to acute coronary artery events in HIV-infected individuals-an international collaborative study
Date of approval: April 2009
Paper: Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study.
Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26. Abstract
H. Schuitemaker, 
P. Reiss.
I08196 The effect of Radio Therapy on CD4 cell count in HIV-infected patients
Date of approval: March 2008
Paper: Prolonged decrease of CD4+ T lymphocytes in HIV-1 infected patients after radiotherapy for a solid tumor 
Sankatsing SUC, Hillebregt MMJ, Gras L, Brinkman K, van der Ende M, de Wolf F, Stalpers LJA, Prins JM 
J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):546-9. Abstract
S.U.C. Sankatsing, 
J.M. Prins, 
A. Verbon, 
L.A. Gras.
 I11095

Quadruple versus triple antiretroviral therapy
Date of approval: 10 augustus 2011
Paper: Quadruple antiretrovirale therapie heeft geen virologisch voordeel bij de behandeling van hiv-naïeve patiënten met een hoge plasma 'viral load'. 
Grijsen ML, Holman R, Gras L, de Wolf F, Prins JM, namens de ATHENA nationale observationele cohort studie.
Tijdschrift voor Infectieziekten vol 6 nr. 4 2011 (In Dutch)
Abstract

Grijsen M
 I09071

The impact of the presence of TAM's including revertants on the compostion and the efficacy of a first line HAART regimen
Date of approval: March 2009

van der Ende M.E., el Barzouhi A., Schutten M., Rijnders B.J.A., e.a.
 I0000

Role of host genetics in the clinical course of HIV infection
Date of approval: 14 february 2006
Paper: Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control.
van Manen D, Gras L, Boeser-Nunnink BD, van Sighem AI, Maurer I, Mangas Ruiz MM, Harskamp AM, Steingrover R, Prins JM, de Wolf F, van 't Wout AB, Schuitemaker H
AIDS. 2011 Nov 28;25(18):2217-26
Abstract

Schuitemaker H., van 't Wout A., de Wolf F.
 I06208

Long-term quality of life and 
self-reported symptoms among HIV-infected patients treated with highly active antiretroviral therapy

Date of approval: December 2006
Paper: Self-Reported Symptoms Among HIV-Infected Patients on Highly Active Antiretroviral Therapy in th ATHENA Cohort in the Netherlands. de Boer M, Prins JM, Sprangers MAG, Smit C, Nieuwkerk PT. 
HIV Clin Trials 2011;12 (3):161-170 Abstract

Sprangers M.A.G., Nieuwkerk P.T.
I07010 Efficacy and safety of dose reductions of efavirenz as part of therapeutic drug monitoring
Date of Approval: January 22, 2007
Paper: Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, Burger DM, Wit FW.
 J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):240-5. Abstract
van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, Burger DM, Wit FW.
I07058 Nevirapine, nelfinavir and other protease inhibitor side effects during pregnancy
Paper: Steady-state nevirapine plasma concentrations are influenced by pregnancy. Nellen JF, Damming M, Godfried MH, Boer K, van der Ende ME, Burger DM, de Wolf F, Wit FW, Prins JM. HIV Med. 2008 Apr;9(4):234-8. Abstract
van der Ende ME, Boer K, Godfried MH, Nellen FJ.
I05011 Atazanavir switch study
Date of Approval: October 10, 2004
Paper: Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir.  van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss P. HIV Clinical Trials. 2009 May-June;10(3):168-80. Abstract
van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss P.
I07020 A longitudinal inter-cohort study on antiretroviral combinations including nevirapine  
Date of Approval: January 23, 2007
Paper: Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. Antivir Ther. 2009;14(7):931-8. Abstract
Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort.
I04031 Heterosexual HIV transmission among migrants originating from Surinam, the Netherlands Antilles and Aruba: the role of traveling to the country of origin 
Date of Approval: July 08, 2004
Paper: Migrants travelling to their country of origin: a bridge population for HIV transmission? Kramer MA, van Veen MG, de Coul EL, Geskus RB, Coutinho RA, van de Laar MJ, Prins M. Sex Transm Infect. 2008 Dec;84(7):554-5. Abstract
Paper: HIV Transmission Patterns among The Netherlands, Suriname, and The Netherlands Antilles: A Molecular Epidemiological Study. Kramer MA, Cornelissen M, Paraskevis D, Prins M, Coutinho RA, van Sighem AI, Sabajo L, Duits AJ, Winkel CN, Prins JM, van der Ende ME, Kauffmann RH, Op de Coul EL.  AIDS Res Hum Retroviruses. 2010 Oct 7. [Epub ahead of print] Abstract
Prins M, Op de Coul E, Kramer MA, Cornelissen MI, van Sighem A, Sabajo LOA, Duits AJ, Prins JM, Kauffman RH, van der Ende ME.
I07087 Combined use of lopinavir/ritonavir and rifampin in HIV patients coinfected with tuberculosis (TB)
Date of Approval: March 23, 2007
Paper: Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM. AIDS 2009, 23:863–867. Abstract
Burger DM, L’homme RF.
I04046 Predictors of frequencies; key characteristics of observational data obtained from HIV-infected patients participating in the national cohort on AIDS therapy evaluation in The Netherlands (ATHENA)
Date of Approval: July 8, 2004.
Paper: The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases. Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. Am J Epidemiol 2006 Apr 1; 163(7): 676-83. Abstract
Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC.
I04044 Semi-parametric accelerated failure time regression analysis with application to interval censored HIV/AIDS data 
Date of Approval: July 8, 2004.
Paper: Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data. Xue H, Lam KF, Cowling BJ, de Wolf F. Stat Med 2006 Nov 30; 25(22): 3850-63. Abstract
Xue H, Lam KF, Cowling BJ, de Wolf F.
I04016 The Genotypic Inhibitory Quotient (GIQ) for Lopinavir 
Date of Approval: April 22, 2004.
Paper: The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM. AIDS 2006 Apr 24;20(7):1069-1071. Abstract
Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM.
I07903 Antiretroviral treatment of primary HIV infection 
Date of Approval:  April 15, 2003
This research is continued through a new research proposal with the following title ‘Primo-SHM’ (I08044) which started as from February 2008.I08044
Prins JM, Steingrover R, Kroon FP, van Valkengoed I.
I07015 Nevirapine hypersensitivity reactions study, 
Paper: Discontinuation of Nevirapine Due to Hypersensitivity Reactions in Patients with Prior Treatment-experience Compared to Treatment-naïve Patients: The ATHENA Cohort Study. Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P. Clin Infect Dis. 2008 Mar 15;46(6):933-40. Abstract
Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.
I08203 Transmission of antiretroviral drug resistant HIV-1 and HIV-1 subtypes in recently infected and therapy-naive individuals in the Netherlands
Date of approval: Oct 21, 2004
Paper: Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration. Antiviral Therapy 2006; 11: 173-17. Abstract
Paper: Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, Berkhout B, Coutinho R, Back NK. Municipal Health Service Amsterdam, The Netherlands. AIDS. 2004 Jul 23;18(11):1571-7. Paper
Coutinho RA, de Wolf F, Prins M.
I17603 Clinical, immunological and virological parameters in a cohort of HIV-2 infected patients in the Netherlands on or off therapy with different antiretroviral regimens
Date of approval: April 20, 2004
Paper: Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. University Hospital Rotterdam, Dijkzigt, Rotterdam, The Netherlands. AIDS. 2003 Jul;17 Suppl 3:S55-61. Paper
van der Ende ME, Schutten M, Osterhaus ADME.
I05515 Defining the prognosis of HIV-1 infected patients treated with potent antiretroviral therapy
Date of Approval: Oct 27, 2005
de Wolf F.
I07403 Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy
Date of Approval: Jan 16, 2003
Paper: Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. Van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM. HIV Med. 2004 Mar;5(2):74-81. Abstract
van Leth F, Wit F, Reiss P,  Schattenkerk JKME, van der Ende ME, Schneider MME, Mulder JW, Frissen PHJ, de Wolf F, Lange JMA.
I07303 Tolerance, safety and efficacy of antiretroviral combination therapy in HIV-infected women
Date of Approval: Jan 16, 2003
Paper: Nelfinavir and nevirapine side effects during pregnancy. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group. AIDS. 2005 May 20;19(8): 795-9. Paper
Paper: Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects. Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME. Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5.
van der Ende ME, Nellen FJ, Godfried MH, Boer K, Dieleman JP, de Wolf F, Schneider MME.
I10303 TRIESTAN (TReatment Interruption in Early STArters - Netherlands)
Date of Approval: Jan 19, 2006
Paper: Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400. Abstract
Presentation: Treatment Interruption in Early Starters in the Netherlands (TRIESTAN): Successful for at Least 36 Weeks. Pogány K, van Valkengoed I, Kroon F, Prins J, Lange J, Brinkman K.
At CROI February 2005 12th conference on retroviruses and opportunistic infections, (Foundation for retrovirology and human health, Alexandria, VA, 2005), chap.584, p.267.
Brinkman K, Pogany K, Prins JM, Kroon FP, Wit F, Lange JMA.
I13018 Efficacy of lamivudine compared to emtricitabine in nevirapine and efavirenz based antiretroviral therapy: an observational retrospective cohort study
Date of approval: June 3, 2013 
B. Rijnders, A. Verbon, C, Rokx, D. van de Vijver
I05548 Incidence of HPV-related anogenital cancers in HIV-infected patients
Date of approval: 2005 
Paper: Gradually decreasing anal cancer incidence in the HIV+ population in the Netherlands after a decade of cART. Richel O, van der Zee RP, Smit C, de Vries HJ, Prins JM. Sex Health 2013 Nov;10(6):586. doi:10.1071/SHv10n6ab33.
O. Richel
I07252 Study on sexual behaviour among HIV infected homosexual men
Date of approval: May 11, 2010
Collection of data from these men has now been incorporaed into the ACS protocols and will continue as part of the ACS; therefore, this project is closed.  
I. Stolte, A. Krol, M. Prins, A. van Eeden, M. Groot.
I05006 Epidemiology and pathology of HIV coinfection with Hepatitis B and C
Date of approval: Jan, 2005 
J.E. Arends, I.M. Hoepelman, C.A.B. Boucher, C. Smit
I08044 Primo SHM R5x4 HAART M. Grijsen, 
M. Welkers
I12106 Differences of HIV-1-infected children in the Netherlands from different countries of origin
Date of approval: 2012
Paper: Country of Birth Does Not Influence Long-term Clinical, Virologic, and Immunological Outcome of HIV-Infected Children Living in the Netherlands: A Cohort Study Comparing Children Born in the Netherlands With Children Born in Sub-Saharan Africa. Cohen S, van Bilsen WP, Smit C, Fraaij PL, Warris A, Kuijpers TW, Geelen SP, Wolfs TF, Scherpbier HJ, van Rossum AM, Pajkrt D. J Acquir Immune Defic Syndr. 2015 Feb 1; 68(2):178-185. Abstract
Cohen S, van Bilsen WP, Smit C, Fraaij PL, Warris A, Kuijpers TW, Geelen SP, Wolfs TF, Scherpbier HJ, van Rossum AM, Pajkrt D
I13153

Factor associated with late diagnosis of HIV in the Netherlands

Paper: Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort. Op de Coul EL, van Sighem A, Brinkman K, Benthem BH, Ende ME, Geerlings S, Reiss P; ATHENA national observational HIV cohort. BMJ Open. 2016 Jan 4;6(1):e009688 Abstract

 

E. Op de Coul, A. van SIghem, K. Brinkman, I. van der Ende, S. Geerlings
I10042

The use of nevirapine dose escalation in patients who switch from efavirenz to nevirapine (discontinued)

D. Burger, M. Blonk, F. Wit, C. Smit, M. van Luin, L. Gelinck, H. Sprenger, P. Koopmans.